Surendra Gupta

Dr. Surendra Gupta


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Obesity Pillars
Verified
Journal Article
Open access
SGSurendra Gupta
Surendra Gupta
PLPurushottam Lal
Purushottam Lal
RSRakesh Sharma
Rakesh Sharma
AGAbhishek Gupta
Abhishek Gupta
BCBrajesh Raj Chaudhary
Brajesh Raj Chaudhary
The purpose of this systematic review was to synthesize current evidence on the effectiveness of family-centered interventions that target parental behaviors such as dietary habits, physical activity, and sedentary patterns, in reducing childhood obesity risk. Rather than examining parental behaviors as independent predictors, this review focuses on interventions designed to modify them. A comprehensive literature search was conducted using electronic databases including Medline/PubMed and EMBASE, supplemented by hand searching. Eligible studies included randomized controlled trials, quasi-experimental, observational, qualitative, and mixed-methods designs involving children aged 0-18 years. Interventions focused on parental behaviors related to diet, physical activity, and sedentary habits. Data extraction was performed independently by two reviewers, with risk of bias assessed using standard tools appropriate to study design. Narrative synthesis and meta-analyses, where appropriate, were conducted using random-effects models to account for study heterogeneity. Five randomized controlled trials met inclusion criteria, encompassing parent-only and family-based behavioral interventions across diverse populations. Parent-focused interventions with booster sessions consistently demonstrated significant reductions in children's body mass index z-scores compared to standard or no intervention. Secondary outcomes, including improvements in dietary habits and psychosocial factors, were reported but with less consistency. Risk of bias was low to moderate overall, though limitations included small sample sizes and variable follow-up durations. Parental involvement is pivotal in pediatric obesity management. Family-centered behavioral interventions, particularly those incorporating booster supports, effectively reduce childhood obesity risk. Limitations of current evidence include methodological heterogeneity and limited long-term data. Future research should focus on paternal roles, diverse populations, and standardized outcome reporting. Systematic review registration: PROSPERO [CRD42025640314].

23 December 2025 in Children
Verified
Journal Article
Open access
PDF file
SGSurendra Gupta
Surendra Gupta
PLPurushottam Lal
Purushottam Lal
Background: Childhood obesity continues to pose a major global health challenge, and schools offer a structured and scalable setting for implementing physical activity programs. However, the effectiveness of these interventions remains inconsistent. This systematic review synthesizes evidence from school-based physical activity interventions and evaluates their impact on obesity-related parameters, physical activity levels, physical fitness, and cardiorespiratory fitness among children. Methods: A comprehensive search of PubMed, Scopus, and the Cochrane Library identified randomized controlled trials published between January 2015 and March 2025. Eligible studies included children aged 5–18 years and assessed school-based physical activity interventions. Outcomes included BMI, body fat percentage, physical activity levels (including MVPA), physical fitness, and cardiorespiratory fitness. Due to methodological heterogeneity, a narrative synthesis was conducted. Results: A total of 28 studies met inclusion criteria. Among the 16 studies reporting obesity-related outcomes, 7 demonstrated statistically significant improvements in BMI or BMI z-scores, while 6 of 16 (37.5%) showed no measurable effect. Reductions in body fat percentage were more consistently observed (5 of 6 studies). Both short-term (12 months) interventions showed comparable proportions of studies with statistically significant BMI improvements (~50%). For physical activity outcomes, 5 of 11 studies reported increased MVPA, whereas others showed no significant change. Sedentary behavior outcomes were mixed, with only 2 of 6 studies demonstrating significant reductions. Improvements in physical fitness were reported in two-thirds of studies, while cardiorespiratory fitness improvements were inconsistent, with significant gains observed primarily in higher-intensity or well-structured programs. Across outcomes, several findings were statistically significant but modest in clinical magnitude. Conclusions: School-based physical activity interventions have the potential to improve select obesity-related parameters, particularly body fat percentage and BMI in a subset of studies. However, effects on MVPA, sedentary time, overall activity levels, and cardiorespiratory fitness remain variable. The effectiveness of these programs appears influenced by intervention structure, intensity, and adherence rather than duration alone. Future interventions should incorporate tailored, multi-component approaches to enhance both clinical relevance and long-term sustainability. While several effects were statistically significant, most were modest in magnitude. However, even modest improvements in BMI z-score, body fat percentage, and fitness can be meaningful at a population level, particularly when delivered through universal, scalable school platforms that reach large numbers of children.

21 November 2025 in Children
Verified
Journal Article
Open access
PDF file
SGSurendra Gupta
Surendra Gupta
PLPurushottam Lal
Purushottam Lal
Objective: Our objective was to determine the relationship between sleep dimensions and obesity risk in the pediatric population. Methods: This systematic literature review was performed following PRISMA guidelines. Peer-reviewed original research focusing on sleep parameters in the pediatric population aged 0–18 years, with obesity risk measured using objective measures, was included. Results: The review analyzed 27 studies, comprising 85,669 participants aged 0–18 years. The majority of the studies observed an inverse relationship between short sleep duration and obesity risk, with insufficient sleep translating to negative weight status, increased waist circumference, and higher obesity prevalence. Sleeping late on both weekdays and weekends increases the risk of obesity. Only four studies assessed sleep quality, with inconsistent findings. Sleep duration and timing had a stronger effect on obesity risk than sleep quality. Conclusions: Sleep duration was an independent determinant of obesity risk in the pediatric population, while sleep timing and quality showed an inconsistent association.

15 February 2026 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
SGSurendra Gupta
Surendra Gupta
PLPurushottam Lal
Purushottam Lal
AGAbhishek Gupta
Abhishek Gupta
BCBrajesh Raj Chaudhary
Brajesh Raj Chaudhary
Childhood and adolescent obesity represent critical global health issues with a rising prevalence and associated cardiometabolic and psychosocial consequences. Pharmacotherapy has emerged as an adjunct treatment to lifestyle modifications in patients with severe obesity or a poor response to behavioral interventions. However, the ethnic and racial variations in drug efficacy and safety remain poorly understood. This systematic review aimed to determine whether ethnicity influences the efficacy and adverse effects of pharmacological treatments for pediatric obesity. A comprehensive literature search was conducted using PubMed, Embase, Scopus, and Cochrane Library databases for studies published between January 2000 and December 2024. Eligible randomized controlled trials included participants aged ≤18 years and reported ethnicity-specific outcomes for antiobesity pharmacotherapy. Of the 3,979 identified records, 4 randomized trials met the inclusion criteria and investigated liraglutide, metformin, phentermine/topiramate, and sibutramine. Across all studies, pharmacotherapy significantly reduced body mass index compared with placebo. This review provides a complete and clearly articulated conclusion reflecting these findings. However, consistent evidence is lacking of ethnicity-based differences in efficacy or safety. One trial suggested a possible trend of reduced responses among African American adolescents receiving sibutramine, although the findings were underpowered and exploratory. Common limitations include minority group underrepresentation, small subgroup sizes, heterogeneous outcome measures, and post hoc analyses of ethnicity. The risk of bias across trials ranged from low to some concern, primarily due to post hoc analyses, incomplete outcome data, and a lack of prespecified ethnicity-stratified outcomes, and limited confidence in the findings. Overall, the current evidence does not support major ethnicity-related differences in the pharmacological management of pediatric obesity, although the certainty of this evidence is low. Larger prospectively designed trials with prespecified ethnic subgroup analyses are urgently needed to establish equitable personalized approaches to pharmacotherapy for childhood obesity. (registration number: CRD42025117631)

12 October 2026 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
PDF file
SGSurendra Gupta
Surendra Gupta
PLPurushottam Lal
Purushottam Lal
Pediatric obesity now affects nearly 1 in 5 children and adolescents in the United States, and its consequences reach well into adult life. For years, clinicians offered little beyond brief advice and a plan to recheck later, an approach that quietly allowed a treatable disease to progress. The 2023 American Academy of Pediatrics guideline broke with that tradition. It treats obesity as a chronic disease and calls for early, intensive treatment that may include medication from age 12 years and metabolic and bariatric surgery from age 13 years. This narrative review summarizes what the authors know about the epidemiology, biology, assessment, and management of pediatric obesity, with a focus on the rapidly changing place of drug therapy. Four medications carry US Food and Drug Administration approval for adolescents: orlistat, phentermine/topiramate extended-release, liraglutide, and once-weekly semaglutide. Of these, semaglutide has shown the greatest effect in randomized trials to date, lowering body mass index by roughly 16% in the STEP TEENS study. Intensive lifestyle treatment remains the foundation at every age, and surgery offers benefit for adolescents with severe obesity. Optimal care also means addressing weight stigma and the social conditions that concentrate risk in disadvantaged communities. The hardest problem now is access: the treatments exist, but they reach children unevenly. Tirzepatide and other newer agents are likely to broaden the options in the near future.